melagatran has been researched along with cyclotheonamide a in 1 studies
| Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (cyclotheonamide a) | Trials (cyclotheonamide a) | Recent Studies (post-2010) (cyclotheonamide a) |
|---|---|---|---|---|---|
| 185 | 32 | 19 | 10 | 0 | 1 |
| Protein | Taxonomy | melagatran (IC50) | cyclotheonamide a (IC50) |
|---|---|---|---|
| Prothrombin | Homo sapiens (human) | 0.7615 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adang, AE; de Man, AP; Grootenhuis, PD; Kelder, J; Lucas, H; Meuleman, DG; Peters, CA; Rewinkel, JB; Smit, MJ; van Aelst, S; van Boeckel, CA; van Dinther, T; Visser, A; Vogel, GM | 1 |
1 other study(ies) available for melagatran and cyclotheonamide a
| Article | Year |
|---|---|
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.
Topics: Administration, Oral; Animals; Aorta; Biological Availability; Biological Transport, Active; Caco-2 Cells; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibrinolytic Agents; Half-Life; Humans; In Vitro Techniques; Models, Molecular; Oligopeptides; Rats; Structure-Activity Relationship; Thrombin; Thrombosis | 2002 |